Acute myeloid leukaemia relapsing following interleukin‐2 treatment expresses the alpha chain of the interleukin‐2 receptor
Authors:
- 1 January 1991
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 77 (1) , 43-49
Abstract
Summary. Immunotherapy with recombinant human Interleukin‐2 (rhIL‐2) was given to nine patients in first complete remission from acute myeloid leukaemia (AML). Five patients relapsed. The median time to relapse after commencing rhlL‐2 was 26 weeks (range 2‐44).Four patients were studied at relapse. The morphological and cytochemical features at relapse and presentation were similar. Cytogenetic analysis at relapse in patients 1 and 3 showed a normal karyotype. At relapse, patient 4 had the abnormality 46,XY, t(2;3). Patient 2 had the chromosomal abnormality t(8;21) at presentation and relapse.Patients 3 and 4 with M5 AML relapsed rapidly at 2 and 9 weeks after starting rhIL‐2 treatment. Relapse leukaemia cells had features normally associated with lymphoid development. Patient 3 was TdT positive, with rearranged immunoglobulin genes, and a proportion of cells expressing the CD7 antigen; patient 4 also expressed the CD7 antigen.Relapse leukaemic cells from three of four patients expressed the α chain of the IL‐2 receptor as assessed by flow cytometry. After overnight incubation and removal of T‐lymphocytes the proportion of cells from these patients expressing the α chain increased from 15% to 61% (P < 0·01). Using tritiated thymidine uptake to assess cell proliferation, two of three patients who expressed the IL‐2 receptor α chain proliferated in response to 1000 u/ml of rhIL‐2 in vitro, with a stimulation index > 1·95 (P < 0·05).Following rhIL‐2 immunotherapy for AML, relapse cells may express an inducible form of the a chain of the IL‐2 receptor, which can mediate a proliferative response. It is possible that rhIL‐2 when administered to AML patients in remission, may induce relapse. This may be a particular risk in patients with the M5 subtype.Keywords
This publication has 29 references indexed in Scilit:
- CD 7 positive acute myeloid leukaemia: a subtype associated with cell immaturityBritish Journal of Haematology, 1989
- IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukaemiaBritish Journal of Haematology, 1989
- Unusual immunophenotypes in acute leukaemias: incidence and clinical correlationsBritish Journal of Haematology, 1989
- Interleukin 2 and its receptor: Structure, function and therapeutic potentialBlood Reviews, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Two tandemly organized human genes encoding the T-cell γ constant-region sequences show multiple rearrangement in different T-cell typesNature, 1985
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984
- Fluorodeoxyuridine synchronization of bone marrow culturesCancer Genetics and Cytogenetics, 1983
- Detection of specific sequences among DNA fragments separated by gel electrophoresisJournal of Molecular Biology, 1975